Does endometriosis or adenomyosis change the plan?
Does endometriosis or adenomyosis change the plan? Yes—GSM (vaginal dryness/atrophy) still responds to non-hormonal moisturisers, suitable lubricants and, when needed, local vaginal oestrogen or DHEA; however, coexisting endometriosis/adenomyosis can add deep pelvic pain, spotting and period-like cramps. We adapt pacing, analgesia, pelvic floor physio, and contraceptive/surgical plans as needed, and review red flags before escalation. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Does endometriosis or adenomyosis change the plan? Often, yes. Genitourinary syndrome of menopause (GSM)—also called vaginal atrophy—arises from low oestrogen, causing dryness, burning, dyspareunia, micro-tears and sometimes urinary urgency/frequency. Foundational care (regular vaginal moisturiser—many prefer hyaluronic acid gels—plus a compatible personal lubricant) remains the first step, and many people need a local therapy such as vaginal oestrogen or vaginal DHEA for tissue recovery. Endometriosis and adenomyosis add a separate—often deeper—pain driver (inflammation, myometrial tenderness, cyclical flares) that can persist pre-menopause, perimenopause and in some post-menopausal scenarios (e.g., with HRT or residual disease). So we treat two problems: the superficial friction pain of GSM and the deep pelvic pain of endometriosis/adenomyosis, each with targeted tools.
What stays the same for GSM: keep external care gentle (lukewarm water; bland emollient as a soap substitute; avoid fragranced washes/bubble baths); schedule a moisturiser 2–4 times weekly; and use a lubricant for higher-friction moments—water-based (versatile, condom-friendly), silicone-based (long-lasting glide for vestibular tenderness), or oil-based (rich feel but may degrade latex condoms/toys). If tenderness concentrates at the entrance (vestibule/posterior fourchette), a cream format can target that area. When GSM limits comfort despite good foundations, add local vaginal oestrogen (cream, pessary/tablet or ring) or vaginal DHEA and review at 6–12 weeks.
What we adjust for endometriosis/adenomyosis: 1) Pacing and positions: choose lower-pressure positions, build unhurried arousal, and stop before pain; consider psychosexual strategies to reduce anticipatory guarding. 2) Pelvic floor physiotherapy: down-training, breath work and graded exposure/dilators to reverse protective tightening at the entrance and address coexisting vestibulodynia. 3) Analgesia and flares: anti-inflammatories around expected flares (if suitable), heat, and flare plans to avoid “boom-and-bust”. 4) Contraception/HRT planning: levonorgestrel IUS or combined strategies may be considered for heavy bleeding/adenomyosis; in surgical menopause or after endometriosis surgery, systemic HRT choices are individual. Local GSM therapy can be used alongside systemic regimens with clinical advice. 5) Diagnosis review: abnormal bleeding, progressive deep dyspareunia, bowel/bladder symptoms, or pain unresponsive to first-line measures merit gynaecology review; imaging or laparoscopy may be discussed in line with guidelines.
When devices or procedures are considered: Energy-based devices (vaginal laser/radiofrequency) and regenerative injectables (e.g., PRP or polynucleotides) are not first-line for GSM; consider only after guideline-led options, with careful counselling on benefits, limits and UK regulation. They do not treat endometriosis/adenomyosis. For a clinic overview of concerns we assess and a step-by-step look at how treatment steps are sequenced, see our internal guides.
Red flags and mimics to check first: fever, foul-smelling discharge, new ulcers/rapidly changing white plaques (e.g., lichen sclerosus), post-menopausal bleeding, visible blood in urine, or severe new pelvic pain all need prompt assessment. Recurrent “thrush-like” irritation with negative swabs often reflects GSM/irritant dermatitis rather than candida; repeating antifungals won’t fix low-oestrogen tissue.
Clinical Context
Who may benefit from a dual-track plan? Those with GSM symptoms (dryness, micro-tears, urine-on-skin sting) plus deep dyspareunia, period-like cramps, heavy/irregular bleeding, or bowel/bladder pain suggesting endometriosis/adenomyosis. Start with moisturiser + lubricant for friction relief and add local oestrogen or DHEA if dryness persists; in parallel, address deep pelvic pain with pelvic floor physiotherapy, pacing, and guideline-directed gynaecology input.
Who needs earlier specialist review? People with persistent deep dyspareunia despite good GSM care; heavy bleeding/clots; intermenstrual or post-coital bleeding; new post-menopausal bleeding; or escalating pelvic pain. Consider imaging, contraception choices (e.g., levonorgestrel IUS) or surgical options under specialist guidance. If systemic HRT is used for vasomotor symptoms, many still need local GSM therapy to improve vaginal comfort.
Next steps. Map symptoms, exclude red flags, build a friction-reduction routine, add local therapy for GSM as needed, and coordinate gynae care for endometriosis/adenomyosis. Review at 6–12 weeks and titrate to the lowest effective maintenance once comfortable.
Evidence-Based Approaches
Guidelines & patient resources (UK): For mechanisms, diagnosis and management of endometriosis see NHS: Endometriosis and the NICE guideline NG73 on endometriosis. For adenomyosis symptoms and options see NHS: Adenomyosis. GSM first-line care and positioning of local therapies are set out in the NICE Menopause Guideline (NG23).
Systematic reviews: Cochrane syntheses report that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, pessaries/tablets and rings, supporting their use when non-hormonal measures are insufficient. See the Cochrane Library for summaries.
Prescribing detail & scope: UK product information and cautions for local vaginal treatments (oestrogen, prasterone/DHEA) are available in the British National Formulary (BNF). These therapies target GSM tissue biology; they do not treat endometriosis/adenomyosis lesions, which follow NG73 pathways (medical, contraceptive and surgical options).
Putting it together: treat GSM with stepped, guideline-aligned measures (moisturiser → local therapy), while managing endometriosis/adenomyosis per NG73 and NHS advice. Use pelvic floor physiotherapy to address guarding/vestibulodynia, and review progress regularly so both superficial (GSM) and deep pain drivers are covered.